We are developing an information capability at the forefront of bringing cancer genomic analysis to the routine care for patients receiving radiation treatments. Our molecular assays are designed to match a patient’s individual molecular alterations with response prediction and relevant targeted therapies in combination with radiation.
Cancer Avatars
Patient-derived xenograft (PDX) mice arguably provide the highest fidelity models of human cancers available without using humans themselves. Donated human tumor tissue are implanted into immunocompromised mice and PDXs are developed. We use these models to advance our biomarker-driven cancer research, preclinical drug testing, and to predict the responses of drugs in individual tumors, also known as our n of one experiments.
Intratumoral Heterogeneity and Therapeutic Resistance Intratumoral heterogeneity can pose a major challenge to effective cancer treatments. For example, subclonal diversity and distinct differentiation states within individual tumors can contribute substantially to phenotypic variability by providing a fitness benefit. This translates clinically into initial response followed by early or late recurrence of the tumor. We seek to understand the genetic and epigenetic changes that provide cancers with adaptation capabilities in order to resist our therapies.

Photography by © Russell Lee